Chugai’s Pockets Are Getting Heavy, So What Next?
This article was originally published in PharmAsia News
Executive Summary
The Roche Group member is looking to spend some cash, but is finding that it’s easier said than done.
You may also be interested in...
Follow The Leader: Bristol Aims To Build On Head Start In Cancer Immunotherapy
The potential for cancer immunotherapy was the clear takeaway from ASCO 2013. With a lead on the competition, a portfolio with a variety of intriguing mechanisms and many combination trials ongoing, Bristol looks to take immuno-oncology development to the next level.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.